An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults
Phase of Trial: Phase I/II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs ABX 464 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Abivax
- 04 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
- 18 Sep 2017 According to an Abivax media release, the first patient has been dosed in the second cohort, initial results of the first cohort are expected in the first week of October and results from cohort are expected in the second quarter of 2018.
- 17 Mar 2017 Status changed from not yet recruiting to recruiting.